{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:49:50Z","timestamp":1777294190691,"version":"3.51.4"},"reference-count":39,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T00:00:00Z","timestamp":1646524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Transplant\u2010associated thrombotic microangiopathy (TA\u2010TMA) is an endothelial injury complication of hematopoietic stem cell transplant (HSCT) leading to end\u2010organ damage and high morbidity and mortality. Defibrotide is an anti\u2010inflammatory and antithrombotic agent that may protect the endothelium during conditioning.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>We hypothesized that prophylactic use of defibrotide during HSCT conditioning and acute recovery could prevent TA\u2010TMA. A pilot single\u2010arm phase II trial (NCT#03384693) evaluated the safety and feasibility of administering prophylactic defibrotide to high\u2010risk pediatric patients during HSCT and assessed if prophylactic defibrotide prevented TA\u2010TMA compared to historic controls. Patients received defibrotide 6.25\u00a0mg\/kg IV q6h the day prior to the start of conditioning through day +21. Patients were prospectively monitored for TA\u2010TMA from admission through week 24 post transplant. Potential biomarkers of endothelial injury (suppression of tumorigenicity 2 [ST2], angiopoietin\u20102 [ANG\u20102], plasminogen activator inhibitor\u20101 [PAI\u20101], and free hemoglobin) were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010five patients were enrolled, 14 undergoing tandem autologous HSCT for neuroblastoma and 11 undergoing allogeneic HSCT. Defibrotide was discontinued early due to possibly related clinically significant bleeding in 12% (3\/25) of patients; no other severe adverse events occurred due to the study intervention. The other 22 patients missed a median of 0.7% of doses (0%\u20135.2%). One patient developed nonsevere TA\u2010TMA 12\u00a0days post HSCT. This observed TA\u2010TMA incidence of 4% was below the historic rate of 18%\u201340% in a similar population of allogeneic and autologous patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study provides evidence that defibrotide prophylaxis is feasible in pediatric patients undergoing HSCT at high risk for TA\u2010TMA and preliminary data indicating that defibrotide may reduce the risk of TA\u2010TMA.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.29641","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T04:31:35Z","timestamp":1646627495000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high\u2010risk pediatric patients"],"prefix":"10.1002","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-3813","authenticated-orcid":false,"given":"Christine S.","family":"Higham","sequence":"first","affiliation":[{"name":"Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, University of California San Francisco Benioff Children's Hospitals  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8371-1040","authenticated-orcid":false,"given":"Kristin A.","family":"Shimano","sequence":"additional","affiliation":[{"name":"Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, University of California San Francisco Benioff Children's Hospitals  San Francisco California USA"},{"name":"Division of Pediatric Hematology and Oncology, University of California San Francisco Benioff Children's Hospital  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Melton","sequence":"additional","affiliation":[{"name":"Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, University of California San Francisco Benioff Children's Hospitals  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandhya","family":"Kharbanda","sequence":"additional","affiliation":[{"name":"Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, University of California San Francisco Benioff Children's Hospitals  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Chu","sequence":"additional","affiliation":[{"name":"Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, University of California San Francisco Benioff Children's Hospitals  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmeen","family":"Dara","sequence":"additional","affiliation":[{"name":"Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, University of California San Francisco Benioff Children's Hospitals  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-1594","authenticated-orcid":false,"given":"Lena E.","family":"Winestone","sequence":"additional","affiliation":[{"name":"Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, University of California San Francisco Benioff Children's Hospitals  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle L.","family":"Hermiston","sequence":"additional","affiliation":[{"name":"Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, University of California San Francisco Benioff Children's Hospitals  San Francisco California USA"},{"name":"Division of Pediatric Hematology and Oncology, University of California San Francisco Benioff Children's Hospital  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James N.","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, University of California San Francisco Benioff Children's Hospitals  San Francisco California USA"},{"name":"Division of Pediatric Hematology and Oncology, University of California San Francisco Benioff Children's Hospital  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6146-3952","authenticated-orcid":false,"given":"Christopher C.","family":"Dvorak","sequence":"additional","affiliation":[{"name":"Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, University of California San Francisco Benioff Children's Hospitals  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,3,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13371"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.11.001"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01283-0"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.06.006"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.207"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501445"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001315"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16457"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00133"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003988"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-564997"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.06.006"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0159-8"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003455"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.39"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703414"},{"issue":"13","key":"e_1_2_8_18_1","first-page":"1049","article-title":"Complement blockade for TA\u2010TMA: lessons learned from large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele S","year":"2020","journal-title":"Blood"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0256-8"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.11.020"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.351"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.1.334"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704930"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.07.001"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-676924"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000230373.82376.46"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.119"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(92)90286-J"},{"issue":"5","key":"e_1_2_8_29_1","first-page":"1038","article-title":"Removal of elevated circulating angiopoietin\u20102 by plasma exchange \u2013 a pilot study in critically ill patients with thrombotic microangiopathy and anti\u2010glomerular basement membrane disease","volume":"104","author":"Lovric S","year":"2010","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2020.12.010"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-321315"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701151"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16557"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001242"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.10.015"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61938-7"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1216"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.161"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.01.002"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01293-y"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29641","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.29641","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T12:45:17Z","timestamp":1692967517000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.29641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,6]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1002\/pbc.29641"],"URL":"https:\/\/doi.org\/10.1002\/pbc.29641","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,6]]},"assertion":[{"value":"2021-09-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e29641"}}